Criteria
known prior exposure to MPXV before vaccination (post-exposure prophylaxis or infection)
known prior MPXV infection before study observation period (01/07/2022)
"history of Guillain-Barré syndrome, dementia, thrombocytopenia, bleeding disorders, alcohol abuse, or drug addiction in the year before October 1, 2018"
"exposure to anticoagulants in the 3 weeks before October 1, 2018"
individuals who died during the 2017–2018 and 2018–2019 influenza seasons without the date or cause of death when count <1%
individuals who received influenza vaccine during 2017–2018 or 2018–2019 seasons lacking vaccination date when count <1%
individuals with documentation of receiving multiple doses of Ad26.COV2.S
individuals who received booster doses of other COVID-19 vaccines
"missing age, sex, insurance type, or region information"
"received influenza or COVID-19 vaccine during August 1–30, 2022 (to exclude prior season vaccination)"
"received more than one influenza vaccine or more than one COVID-19 vaccine during August 31, 2022–July 31, 2023"
"in influenza cohort, received COVID-19 vaccine between index date and July 31, 2023"
"in co-admin cohort, received influenza and COVID-19 vaccines on separate days"
received PPV23 more than 1 year before 65th birthday
received more than two PPV23 doses
had asplenia or chronic renal disease
record of immunization with PCV at any point
received PPV23 before CPRD registration date + 28 weeks (to avoid counting historical records as current)
older adults who received PPSV-23 with non-influenza vaccines on the same day
received non-influenza vaccines or more than two influenza vaccine doses within a year before PPSV-23 vaccination
individuals with prespecified event occurrence before start of follow-up cohort
followed up less than 6 months
vaccinated not following EMA standard operating procedure recommendations
codification errors or missing information
vaccinated in private centers (visits not registered in VID)
no primary care visit in the first 2 months of age
patients admitted directly to Intensive Care Units were excluded
"osteoarthritis, fibromyalgia, or crystalline arthritis without concomitant SARD diagnosis"
received Ad26.COV2.S (Janssen/Johnson & Johnson vaccine)
missing covariates for propensity score calculation
missing symptom onset date (excluded from both PEPL and PEPF analyses)
"for PEPL analysis: missing last exposure date, mpox disease on or before last exposure date, or JYNNEOS mpox vaccine administered before last exposure date"
for PEPF analysis: missing first exposure date
individuals with inconsistent first/last exposure documentation analyzed in only one of PEPL or PEPF groups with possible differing classification
early vaccinated children (potentially severe conditions differing from general population)
prior infected patients (to focus on vaccine immunity only)
cases with other comorbidities excluded
patients with primary COVID-19 diagnosis but no positive SARS-CoV-2 test excluded
excluded 3 patients who died during first 24 hours of hospitalization
"unreliable vaccination data (30,408"
0.9%)
"<1 year of continuous registration (109,524"
3.3%)
"health or social care worker (4,728"
0.1%)
"care or nursing home resident or medically housebound (162,552"
5.1%)
"receiving end-of-life care (50,322"
1.7%)
"missing demographic information (149,880"
5.1%)
"evidence of SARS-CoV-2 infection prior to December 8, 2020 (38,910"
1.4%)
record of receiving PPV23 before cohort entry
received PPV23 more than once
missing lot number for PPV23
observation ended in month of cohort entry
residency less than 1 year
patients with progressive MS course or myelin oligodendrocyte glycoprotein-IgG associated disorder (excluded due to small sample size)
patients who did not reside in New York (excluded to ensure reliable vaccination data capture)
"no VA encounters in 12 months prior to vaccination (n = 133,776)"
"residing in VA long-term care facilities (n = 16,437)"
"evidence of SARS-CoV-2 infection prior to vaccination date (n = 87,555)"
no mother–offspring linkage
multiple births
maternal membership <1 year prior
"missing key covariates (e.g., LMP date, SES)"
births in January–February 2021 with prenatal vaccination (bias toward preterm)
any HZ diagnosis in prior 12 months
"residence in nursing home, SNF, or hospice at index"
enrollment in Medicare Part C
missing or conflicting age or sex
COVID-19 diagnosis or treatment 90 days prior to index through CED
evidence of mRNA-1273.815 from 60 days prior to index through CED (except exposed on index)
receipt of any other COVID-19 vaccine from 60 days prior to index through CED
less than 1 day of follow-up
missing ZIP codes
received any RSV vaccination before trial month start
positive RSV test within 90 days before trial month start
positive RSV test during days 0–13 after index date (for primary analysis)
received a non-mRNA COVID-19 vaccine up to and including index date
received more than one mRNA vaccine dose on day 0
received any COVID-19 vaccine during days 1–13 inclusive
diagnosed with COVID-19 or related infectious disease during days 0–13 inclusive
missing or unknown sex or age on index date
missing or unknown geographic region
test-confirmed SARS-CoV-2 infection within 90 days before index date
received any SARS-CoV-2 vaccine within 134 days before index date (4 months + 14 days grace period)
receiving hospice care
patients with demographic data inconsistencies
previously documented positive SARS-CoV-2 PCR test
history of potential adverse event of interest
hospital admission within 6 months prior to index date (including long-term care facility residents)
emergency department visit within 7–90 days prior to index date
application for Relieved Co-payment Policy within 365 days prior to index date
"previously documented hepatitis B or C (ICD-10: B16, B17, B18)"
"history of anaphylaxis (ICD-10: T78.2, T88.6, T78.0, T80.5) as of index date"
contraindication to vaccination (monoclonal antibody treatment within prior 90 days or COVID-19 diagnosis within prior 30 days)
hospitalization within prior 30 days
"diagnosis of HIV, active cancer, dementia, or palliative care treatment within prior year"
"systemic GDs, vasculitis, hepatitis B or C, HIV, or malignancy occurring within 5 years before enrollment"
codes for dialysis or solid organ transplantation
experienced outcome prior to start of outcome window (excluded from that analysis year)
record of both vaccine brands at index date
"vaccination against influenza between December 23, 2014 and June 30, 2015"
received SARS-CoV-2 infection diagnosis before index date
received a different COVID-19 vaccine prior to index date
living in the community without a vaccination record who delayed the second dose beyond 6 weeks and did not receive three doses of either mRNA-1273 or BNT162b2
non-immunocompromised participants who received the third dose within 5 months
immunocompromised participants who received the third dose within 2 months
"record of influenza vaccination between May 19 and July 31, 2019"
"record of influenza-related medical encounter before vaccination or before September 30, 2019"
aged ≥9 years who received two influenza vaccine doses
"missing information on age, sex, or geographic region"
multiple gestations (for primary outcomes)
fetuses or infants with congenital anomalies (for primary outcomes)
pregnancies not meeting gestational week window (20–43 weeks entirely within study period)
not a health or social care worker
not resident in a care or nursing home
not medically housebound or receiving end-of-life care
evidence of SARS-CoV-2 infection or COVID-19 within the previous 28 days
admitted to hospital at the time of boosting
"missing information on sex, deprivation, or Sustainability and Transformation Partnership"
testing within 2 weeks of vaccination
received two different types of influenza vaccine in the same season
received a high-dose or adjuvanted influenza vaccine
missing vaccination data
had an immunocompromising condition
positive test within the last 12 weeks before index date
"excluded 141,503 persons with documented SARS-CoV-2 infection (20,105)"
"died (34,614)"
"received a third vaccine dose (107,156) between April 20 and September 22, 2021"
residents who received 1-dose Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine (small numbers)
SARS-CoV-2 infection in previous 90 days
planned discharge according to most recent assessment
treatment with monoclonal antibodies in previous 90 days
receiving hospice care
received third vaccine dose before index date
"evidence of SARS-CoV-2 infection before December 1, 2021 (VA and CMS data)"
incongruent first and second doses of primary vaccine
missing residential address
"no inpatient, outpatient, or primary care encounter in VA health system in preceding 24 months"
not assigned to a unique Veterans Integrated Services Network (VISN)
evidence of COVID-19 infection before index date or within 13 days after index date
receipt of heterologous COVID-19 vaccine within 365 days before or 13 days after index date
receipt of additional homologous COVID-19 vaccine dose within 13 days after index date
missing or unknown sex on index date
additional details in supplementary text
received Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine at any time
"received mixed vaccine doses (e.g., Ad26.COV2.S followed by mRNA-1273 or BNT162b2)"
vaccine brand unspecified (unspecific vaccine codes)
received second vaccine dose within 14 days of first dose (likely data error)
clinically extremely vulnerable individuals
HPV-vaccinated before study start
congenital malformations of genitalia (ICD-10 Q50–Q56)
chromosomal abnormalities (Q90–Q99)
"censored if diagnosed with cancer/carcinoma in situ (C00–C99, D00–D09)"
censored if diagnosed with hypogonadism after ovarian treatment (E89.4)
censored if major surgical procedure on genitalia
women who received influenza vaccination less than 2 weeks before delivery
vaccination date outside campaign period
conservative management
previous hysterectomy
persistent or progressive disease at first follow-up
neurological or psychiatric disorders
pregnancy
"chronic systemic, metabolic, or autoimmune disorders"
incomplete reports
no consent
diagnosed with HZ or HZO
classified as immunocompromised within 1 year before index date
"received only a single dose of RZV or a dose of RZV before January 1, 2018"
HZ/HZO diagnosis between two doses
HZ/HZO diagnosis ≤30 days after second dose
received a combination of mRNA and viral vector vaccine doses
"resided in a nursing home between September 1, 2020 and September 1, 2022"
"received hospice care between September 1, 2020 and September 1, 2022"
COVID-19 infection or diagnosis within 90 days before September 2022
received any COVID-19 vaccination in the prior 3 months
tested positive for SARS-CoV-2 in the prior 3 months
received an updated COVID-19 vaccine at any time
"documented positive polymerase chain reaction (PCR) test result for mpox before June 12, 2022"
documented history of COVID-19 infection
dead at the date of vaccination
received second mRNA COVID-19 vaccine dose ≤3 days after first dose
children <5 years of age
recipients of non-mRNA COVID-19 vaccines
received second dose more than 180 days after first dose
participants becoming vaccinated during follow-up (unvaccinated control group members no longer eligible)
participants becoming vaccinated during follow-up (unvaccinated control group members no longer eligible)
died before the start of follow-up
died during follow-up with no ascertained date of death
record of previous infection
interactions with the healthcare system within 3 days before index date
SARS-CoV-2 infection before vaccination date
residence in VA long-term care facilities
individuals <18 years old
non-Malaysian individuals with previous infection
